key: cord-0834009-7objlrqa authors: Lee, Todd C; Morris, Andrew M; Grover, Steven A; Murthy, Srinivas; McDonald, Emily G title: Outpatient Therapies for COVID-19: How do we choose? date: 2022-01-19 journal: Open Forum Infect Dis DOI: 10.1093/ofid/ofac008 sha: f2f0cd62216653185754c0a6e15f145e12859a7d doc_id: 834009 cord_uid: 7objlrqa BACKGROUND: Several outpatient COVID-19 therapies have reduced hospitalization in randomized controlled trials. The choice of therapy may depend on drug efficacy, toxicity, pricing, availability, and available infrastructure. To facilitate comparative decision making, we evaluated the efficacy of each treatment in clinical trials and estimated the cost per hospitalization prevented. METHODS: Wherever possible, we obtained relative risk for hospitalization from published randomized controlled trials. Otherwise, we extracted data from press releases, conference abstracts, government submissions, or preprints. If there was more than one study the results were meta-analyzed. Using relative risk, we estimated the number needed to treat (NNT), assuming a baseline hospitalization risk of 5% and compared the cost per hospitalization prevented with the estimate for an average Medicare COVID-19 hospitalization ($21752). Drug pricing was estimated from GoodRx, from government purchases, or manufacturer estimates. Administrative and societal costs were not included. Results will be updated online as new studies emerge and/or final numbers become available. RESULTS: At a 5% risk of hospitalization the estimated NNT was 80 for fluvoxamine, 91 for colchicine, 72 for inhaled corticosteroids, 24 for nirmatrelvir/ritonavir, 50 for molnupiravir, 28 for remdesivir, 25 for sotrovimab, 29 for casirivimab/imdevimab, and 29 for bamlanivimab/etesevimab. For drug cost per hospitalization prevented colchicine, fluvoxamine, inhaled corticosteroids, and nirmatrelvir/ritonavir were below the Medicare estimated hospitalization cost. DISCUSSION: Many countries are fortunate to have access to several effective outpatient therapies to prevent COVID-19 hospitalization. Given differences in efficacy, toxicity, cost and administration complexities, this assessment serves as one means to frame treatment selection. M a n u s c r i p t The COVID-19 pandemic has fueled an explosion of scientific inquiry. Since the initial reports of overwhelmed health systems and hospitals, there has been tremendous interest in finding outpatient treatments which could prevent hospitalization among those who are symptomatic and at high risk for clinical deterioration. Initial studies looked at drug repurposing: identifying widely available, inexpensive, and safe medications that could prove effective. Initially, hydroxychloroquine was considered a leading candidate (1); however, interest waned as randomized controlled trial evidence failed to demonstrate superiority over placebo (2, 3) . Since that time, there have been a number of promising repurposed medications including colchicine (4) , inhaled corticosteroids (5) , and fluvoxamine (6) (7) (8) all of which have shown a relative risk reduction of 20-30% in hospitalization. Novel therapeutics have emerged, such as customized anti-spike protein monoclonal antibody products, which have shown up to a 55-85% relative risk reduction in hospitalization (9) (10) (11) . However, these therapies are not always widely available, are more challenging to administer, comparatively expensive, and may have reduced efficacy against newer variants. Most recently, repurposed and novel antiviral therapies have attracted attention, with relative risk reductions of 30-85% (12-16). The US government has proactively purchased these agents based on pre-published data (17, 18) . For policy makers and/or healthcare professionals, especially those without ready access to novel therapeutics, the decision might be between supportive care or repurposed drugs. For well-resourced healthcare systems such those in North America, the anti-spike monoclonal antibodies, remdesivir, and oral antiviral therapies cost significantly more, are available in relatively limited quantities, and can be more complex to procure and/or administer. Our objective was to systematically quantify the effect sizes of available A c c e p t e d M a n u s c r i p t treatments with respect to preventing hospitalization and then to contextualize those results against the expected drug costs per hospitalization prevented. To balance efficacy with potential toxicity, the outcome of interest we selected was all-cause hospitalization among outpatients. Where this was unavailable, we used COVID-19 related hospitalization (and have indicated this). Of note, use of the later could underestimate toxicity, as hospitalizations due to drug side effects might be excluded. We used these results to calculate the relative risk for hospitalization with 95% confidence intervals. Results for colchicine were taken from COLCORONA (4) and PRINCIPLE (19) and meta-analyzed using a fixed-effects model (I 2 = 0.0%). For the inhaled corticosteroids, we used the results of our fixed-effects meta-analysis (5) of all available trials (20-23) with the caveat that the fixed-effects model may overestimate efficacy (I 2 = 49.2%). For fluvoxamine, we obtained the number of all-cause hospitalizations in both arms directly from the authors of the three completed clinical trials (6, 7, 24) . In the TOGETHER trial, (7) the authors originally included ER visits of ≥6 hours as a proxy for hospitalization due to the prohibitive number of admissions in Brazil exhausting capacity. To be more conservative, we chose only to include patients who spent more than 24 hours in the emergency department as equivalent to being hospitalized. The trial results were combined using a fixed effects meta-analysis (8) (I 2 = 0.2%). Results for outpatient anti-spike protein antibody randomized controlled trials were limited to most recent phase 3 studies as most used an integrated phase 1/2/3 design that led to multiple publications describing the same patients. We limited our analysis to the latest A c c e p t e d M a n u s c r i p t phase 3 studies for bamlanivimab/etesevimab (9) , casirivimab/imdevimab (10) and sotrovimab (11) . Bamlanivimab monotherapy was not included as it is no longer a recommended treatment. Of important note, it appears that casirivimab/imdevimab and bamlanivimab/etesevimab may not be effective against the Omicron variant (25) . Results for outpatient antiviral therapies included one phase 3 trial of remdesivir (15) . For molnupiravir, we included the published phase 3 trial (14), the analogous subgroup (≤5 days of symptoms and at least 1 high risk criterion) from the phase 2 trial (26) , and a press release from an Indian trial (12) (fixed-effects model I 2 = 47%; may overestimate efficacy). For nirmatrelvir with ritonavir we relied on the FDA emergency use authorization (16) and press release interim analysis for a second trial (13). Random-effects meta-analysis was conducted for a sensitivity analysis and is presented in the Supplement. Recognizing that the field moves very quickly, we have developed a webpage (https://read.idtrials.com/outptcovid) which will be updated monthly at least until the end of 2022 to contain the most up-to-date efficacy and cost data possible. Where available, the lowest drug pricing was taken from GoodRx (www.goodrx.com). We chose budesonide for the inhaled corticosteroid analysis because it was the first corticosteroid to demonstrate a reduction in hospitalizations (22) . For antiviral and monoclonal antibody therapies, we used any publicly available data on US government purchasing and/or the manufacturer's quoted price. Prices for injectable agents did not include the price of administration, which will vary across the agents. Societal costs were also not factored in and are beyond the scope of this analysis. A c c e p t e d M a n u s c r i p t For each drug, we took the estimates of relative risk of hospitalization and the 95% confidence interval to generate the estimated absolute risk reduction (and confidence interval) assuming a moderate baseline risk of hospitalization of 5%. Sensitivity analyses were conducted for 2.5% (low) and 10% (high) risk of hospitalization. For colchicine, where the confidence interval touched 1.00 in the meta-analysis, we used an upper bound of 0.999 for calculating the NNT. By dividing 100 by the absolute risk reduction (rounded up), we estimated the number needed to treat (NNT) to prevent one hospitalization with corresponding confidence intervals. We then multiplied the NNT by the drug costs per patient treated to arrive at the estimated drug cost to prevent one admission. For comparison, the mean cost of a COVID-19 admission to Medicare has been estimated at $21752 (27). This study does not include factors necessitating patient consent. The included studies are summarized in Table 1 . The results of the analysis are presented in Figure 1 and Table 2 with random effects meta-analysis presented in Supplemental Figure 1 . The repurposed drugs fluvoxamine, colchicine, and the inhaled corticosteroids had smaller effect sizes and larger numbers needed to treat assuming a 5% hospitalization risk at 80 (48-667), 91 (52-20000), and 72 (45-400), respectively. By contrast, the antiviral and antibody therapies had larger effect sizes and smaller numbers needed to treat at 24 (22) (23) (24) (25) (26) (27) (28) (29) for nirmatrelvir/ritonavir (Covid-19 hospitalization); 28 (23-80) for remdesivir; 50 (36-118) for molnupiravir; 25 (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) for sotrovimab, 29 (25-37) for casirivimab/imdevimab and 29 (24- A c c e p t e d M a n u s c r i p t 50) for bamlanivimab/etesevimab (Covid-19 hospitalization). However, the latter two antibody therapies likely do not retain activity against Omicron (25) . At a 5% risk of hospitalization, the corresponding drug costs per hospitalization prevented were: $1122 ($673-$9355) for fluvoxamine; $3333 ($1905-$732600) for colchicine; $9475 ($5922-$52640) for inhaled corticosteroids; $12720 ($11660-$15370) for nirmatrelvir/ritonavir; $35000 ($25200-$82600) for molnupiravir; $52416 ($43056-$149760) for remdesivir; $52500 ($46200-$81900) for sotrovimab; $60900 ($52500-$77700) for casirivimab/imdevimab; and $60900 ($50400-$10500) for bamlanivimab/etesevimab. Scientific advancement has been exponential during the pandemic. We have gone from the discovery of a new disease with no treatment in December 2019 to numerous effective vaccines coupled with a suite of proven therapies that prevent hospitalization and, by extension, presumably impact progression to death. Within these treatments, several are inexpensive and widely available worldwide, while others are expensive, limited in availability, and/or limited in accessibility. The purpose of this review was to contrast the efficacy of these therapies against a measure of cost. Evidence suggests that the antiviral therapies and monoclonal antibodies are more effective than repurposed drugs. While we show that this efficacy comes at a price which often exceeds that of COVID-19 hospitalization, this was not a formal cost-effectiveness analysis and we did not factor in death, long term outcomes, societal costs, patient preferences nor costs of administration. The higher an individual's baseline risk of deterioration, the greater the absolute benefit and less costly these options become. If one conservatively estimates a risk of death of 5-10% for those who are hospitalized, the NNTs for death (and costs) would be approximately 10-20 A c c e p t e d M a n u s c r i p t times higher. Furthermore, some of these therapies have already been purchased, which necessarily alters the dialogue. Essentially, at the right price or if prescribed to a high enough risk individual, most drugs on this list have the potential to be cost saving to the system as a whole. Accurate country specific models for prediction of hospitalization risk will be essential in contextualizing and maximizing the benefits of any therapy. This analysis has several limitations. First, most of the agents studied have only had a single positive randomized controlled trial and several are pre-publication. Replication in science is important and while the pandemic necessitated speed which led to single trials, with many vaccinations and outpatient therapy options now available the safeguards of confirmatory trials are likely needed for reproducibility and generalizability. Second, some of the data is currently limited to government documents and press releases. In normal times, peer reviewed results would be required; however, major decisions are being made based on industry public relations material, confidential submissions, and limited data (17,18) and our analysis can serve to inform those conversations elsewhere. Third, our sensitivity analysis for the inhaled corticosteroids found the benefits were not statistically significant in the randomeffects model and thus, the results of this current analysis are predicated on additional trials confirming these drugs have benefit. Fourth, the efficacy of anti-spike protein antibodies require ongoing confirmation for emerging variants, as there are suggestions that some therapies may no longer be as effective against Omicron (25) . Fifth, two molnupiravir (14, 26) and one fluvoxamine (7) trials included emergency room visits of greater than 24 hours in their outcomes which may not necessarily be completely exchangeable with hospitalizations. Sixth, drug prices from GoodRx likely represent the lowest drug pricing and costs for some patients could be substantially higher. Finally, very few patients in these clinical trials were vaccinated and the risk for hospitalization may not be the same in vaccinated patients. Nonetheless, hospitalization in vaccinated patients can be estimated (28) and this is one of the A c c e p t e d M a n u s c r i p t reasons we present sensitivity analyses for different baseline risks of hospitalization. Prospective studies in vaccinated patients are urgently needed. There is an ongoing need to identify effective treatments that can be administered early in the disease to prevent COVID-19 hospitalization and death and to make them available and accessible in all regions. While many countries worldwide are fortunate to have access to novel treatments, the number and location of available doses may wax and wane over time and access may be challenging in remote regions or in congregate care settings. Some degree of decision making will be required at the level of the individual clinician, hospitals, and regional and federal governments to prioritize deployment of therapies and capacity building. This analysis provides one means of contextualizing those discussions. A c c e p t e d M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t A c c e p t e d M a n u s c r i p t Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial Inhaled Corticosteroids for Outpatients with Covid-19: A Meta-Analysis. medRxiv Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis. medRxiv REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 Effect of the Neutralizing SARS-CoV-2 Antibody Sotrovimab in Preventing Progression of COVID-19: A Randomized Clinical Trial. medRxiv Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death | Pfizer Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19 US Department of Health and Human Services. Biden Administration announces U.S. government procurement of Merck's investigational antiviral medicine for COVID-19 treatment Million Courses of Pfizer's COVID-19 Oral Antiviral Medicine as Additional Tool to Reduce Hospitalizations and Save Lives millioncourses-pfizers-covid-19-oral-antiviral-medicine-as-additional-tool-reduce-hospitalizationssave-lives.html 19. PRINCIPLE Trial Collaborative Group Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial. medRxiv Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. The Lancet Respiratory Medicine Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial Fluvoxamine for Early Treatment of Covid-19: a Fully-remote, Randomized Placebo Controlled Trial mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. medRxiv Patient Characteristics and Costs Associated With COVID-19-Related Medical Care Among Medicare Fee-for-Service Beneficiaries Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities. The Journal of Infectious Diseases GoodRx) may underestimate the costs of acquisition for patients/drug plans A c c e p t e d M a n u s c r i p t *Fixed effects models had moderate heterogeneity **All cause hospitalization not provided; COVID-19 related hospitalizations used which may inflate efficacy Monoclonal antibody and remdesivir prices do not include price of administration.Shaded monoclonal antibodies likely have significantly reduced efficacy against the Omicron variant